Vigamox
On the Bulgarian pack: ВИГАМОКС 5 mg/ml капки за очи, разтвор
5 mg/ml eye drops, solution · eye drops solution
- Prescription only
- Eyes and ears
- Active substance
- Moxifloxacin
- Used in
- Eyes and ears
- Made by
- Novartis Europharm Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet read the official leaflet for this product. The exact uses and dose are in the leaflet inside the pack. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (moxifloxacin). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Moxifloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology ( 12.4 )].
Approximately 52% of an oral or intravenous dose of moxifloxacin is metabolized via glucuronide and sulfate conjugation.
The sulfate conjugate (M1) accounts for approximately 38% of the dose, and is eliminated primarily in the feces.
Co-administration with a high fat meal (that is, 500 calories from fat) does not affect the absorption of moxifloxacin.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-17
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (moxifloxacin). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Fluoroquinolones, including moxifloxacin tablets, may exacerbate muscle weakness in patients with myasthenia gravis.
- Moxifloxacin tablets are contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antibacterials [see Warnings and Precautions ( 5.8 )].
- Known hypersensitivity to moxifloxacin tablets or other quinolones ( 4, 5.8 )
The most common adverse reactions (>0.3%) leading to discontinuation with the 400 mg oral doses were nausea, diarrhea, dizziness, and vomiting.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Spain5 matching products
CanadaNo exact match for this strength and form
Netherlands3 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Europharm Limited · Ireland |
|---|---|
| Active substance | Moxifloxacin |
| Used in | Eyes and ears |
| Strength | 5 mg/ml eye drops, solution |
| Form | eye drops solution |
| Pack sizes | 1 |
| Classification | S01AE07 · Eyes and ears |
| Name in the register | ВИГАМОКС 5 mg/ml капки за очи, разтвор |
| Reg. no. | 20090230 |
Source: Bulgarian Drug Agency register · 2026-08-01 · not reviewed by a clinician
Източник: Изпълнителна агенция по лекарствата (ИАЛ). The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.